US Patent

US10085974 — Dosage and formulation

Method of Use · Assigned to Almirall SA · Expires 2029-03-13 · 3y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition for inhalation that contains a dry powder of aclidinium bromide in a specific dose.

USPTO Abstract

The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.

Drugs covered by this patent

Tudorza Pressair (ACLIDINIUM BROMIDE) · Covis

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2513`	—	Tudorza Pressair
`U-2513`	—	Tudorza Pressair

Patent Metadata

Patent number: US10085974
Jurisdiction: US
Classification: Method of Use
Expires: 2029-03-13
Drug substance claim: No
Drug product claim: Yes
Assignee: Almirall SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.